


Derbyshire Symptom Management Guidelines for last days of life

PRESCRIBING SUBCUTANEOUS OPIOID IN THE LAST DAYS OF LIFE	Page 2
RETAINED SECRETIONS IN THE LAST DAYS OF LIFE	Page 3
TERMINAL RESTLESSNESS AND AGITATION	Page 4
NAUSEA IN THE LAST DAYS OF LIFE	Page 5
TERMINAL BREATHLESSNESS	Page 6
GUIDELINES FOR CARE OF DIABETIC PATIENTS IN THE LAST DAYS OF LIFE	Page 7
PALLIATIVE CARE DOSE EQUIVALENCE GUIDANCE	Page 8 & 9

PRESCRIBING SUBCUTANEOUS OPIOID IN THE LAST DAYS OF LIFE




To calculate subsequent doses of Diamorphine over 24 hours:
Review the doses of prn analgesia given in the previous 24 hour period. If more than one dose has been required, other than to pre-empt during care, (e.g. before a dressing etc.) then consider a 30% to 50% increase in the daily subcutaneous dose. If this is not controlling the pain or doses need escalating on a daily basis, seek specialist advice.

**If renal function is impaired, consider reducing the dose of Diamorphine and increasing the prn dosing interval.
If oxycodone is being used in place of Diamorphine refer to Dose Equivalence Guidance Chart.**


IF SYMPTOMS PERSIST – SEEK SPECIALIST ADVICE FROM YOUR LOCAL PALLIATIVE CARE TEAM

RETAINED SECRETIONS IN THE LAST DAYS OF LIFE




IF SYMPTOMS PERSIST – SEEK SPECIALIST ADVICE FROM YOUR PALLIATIVE CARE TEAM

TERMINAL RESTLESSNESS AND AGITATION




IF SYMPTOMS PERSIST – SEEK SPECIALIST ADVICE FROM YOUR PALLIATIVE CARE TEAM

NAUSEA IN THE LAST DAYS OF LIFE



IF SYMPTOMS PERSIST – SEEK SPECIALIST ADVICE FROM YOUR PALLIATIVE CARE TEAM

TERMINAL BREATHLESSNESS



IF SYMPTOMS PERSIST – SEEK SPECIALIST ADVICE FROM YOUR PALLIATIVE CARE TEAM

GUIDELINES FOR CARE OF DIABETIC PATIENTS IN THE LAST DAYS OF LIFE

Practical points:-

1. Ensure any clinical deterioration is not due to reversible hyperglycaemia or hypoglycaemia before making further management decisions particularly if the deterioration is unexpected.
2. Regularly review the patient and their diabetes management plan as their condition changes in the **last year** of life.
3. If your patient is in the **last WEEKS** of life, refer to other guidance <https://www.diabetes.org.uk/end-of-life-care>
Aim of treatment is to avoid symptoms of hyperglycaemia and hypoglycaemia, tight control is not necessary
4. If a patient has been recognised to be dying and believed to be in the **last DAYS** of life, insulin and oral agents can usually be stopped.
 - a. Blood or urine glucose monitoring should be kept to the minimum necessary and stopped if causing distress to the patient.
 - b. If death imminent i.e. expected in less than 24 hours, it may be appropriate to discontinue all monitoring and insulin, usually after discussion with the family.
5. **SEEK SPECIALIST ADVICE IF UNCERTAIN**
 - In usual office hours, your local Palliative Care Team
 - Community Diabetes Specialist Nurse
Monday to Friday, in office hours, usually 9am to 5pm. Tel 01629 817878 Mobile 07884415168 or 07900584162
 - Out of Hours Ashgate Hospice Tel: 01246 568801
 - Out of Hours Nightingale Macmillan Unit Tel: 01332 786040

PALLIATIVE CARE DOSE EQUIVALENCE GUIDANCE (1 of 2)

These dose equivalents are approximate and may need to be adjusted according to response

Total oral Morphine 24 hour	Zomorph or MST twice daily po	Morphine hourly po prn dose	Diamorphine hourly sc prn dose	Diamorphine sc in 24 hours	Oxycodone MR(Oxycontin) twice daily po	Oxycodone immediate release (Oxynorm) hourly po	Oxycodone hourly sc prn dose	Oxycodone s/c in 24 hours	Fentanyl patch 72 hourly**	Buprenorphine patch per hour
20mg	10mg	2.5mg	1.25mg	7.5mg	5mg	1mg	*	*	*	5mcg (Bu Trans)
30mg	15mg	5mg	2.5mg	10mg	5-10mg	2.5mg	*	7.5mg	12mcg	10mcg (Bu Trans)
40mg	20mg	7.5mg	2.5mg	15mg	10mg	2.5mg	*	10mg	12mcg	15mcg (Bu Trans)
60 mg	30 mg	10mg	5 mg	20 mg	15 mg	5 mg	2.5mg	15 mg	25mcg	20mcg (Bu Trans)
90mg	40mg	15mg	5mg	30mg	20mg	7.5mg	4 mg	20mg	37mcg	Suggest use Fentanyl Patch
120 mg	60 mg	20 mg	7.5mg	40 mg	30 mg	10 mg	5 mg	30mg	50mcg	“
180 mg	90 mg	30 mg	10 mg	60 mg	45 mg	15 mg	7.5 mg	45 mg	75 mcg	“
240 mg	120 mg	40 mg	15 mg	80 mg	60 mg	20 mg	10 mg	60 mg	100mcg	“
300 mg	150 mg	50 mg	20 mg	100 mg	75 mg	25mg	12.5 mg	75 mg	100 mcg	“
360 mg	180 mg	60 mg	20 mg	120 mg	90 mg	30 mg	15 mg	90mg	100 mcg	“
400 mg	200 mg	70 mg	20 mg	140 mg	100 mg	35 mg	17.5 mg	100mg	125 mcg	“
480mg	240 mg	80 mg	30 mg	160 mg	120 mg	40 mg	20 mg	120 mg	125 mcg	“
540 mg	260 mg	90 mg	30 mg	180 mg	130 mg	45 mg	22.5 mg	130mg	150 mcg	“

. * Dose too small to be used practically. Consider alternative medication. ** Ref PCF 5 p666 Table 1. Doses based on conversion ratio of 150:1

PALLIATIVE CARE DOSE EQUIVALENCE GUIDANCE 2 of 2

Breakthrough analgesia

Dose of Opioid should be **1/6th** of the total daily dose (dose over 24 hours). This is the same as the four hourly dose

Conversion guidance for weak Opioids

Tramadol

Tramadol po100mg = Morphine po 10mg

Tramadol po 100mg four times daily (400mg/24 hours) = Morphine po 40mg/24 hours.

Codeine

Codeine po 30mg = Morphine po 3 mg

Codeine po 60mg four times daily (240mg/24 hours) = Morphine po 24mg/24 hours

Opioids in renal impairment

Morphine, diamorphine, codeine, tramadol and oxycodone are metabolised to active metabolites which are excreted by the kidneys. In renal failure, metabolites can accumulate and have the potential to cause opioid toxicity but there is considerable interpersonal variation. Symptoms of opioid toxicity can be reduced in some patients by switching to an alternative opioid such as oxycodone or fentanyl, however there is a risk of losing the analgesic benefit of one opioid during rotation to another and this may be detrimental to care in the last days of life.

In the last days of life if renal function is impaired, consider:

1. Reducing the dose of diamorphine or morphine and increasing the prn dosing interval.
2. Managing toxicity using haloperidol for nausea and hallucinations and midazolam for myoclonus if present